Staphylococcus aureus BM4626 (ciprofloxacin MIC, 0.5 ,Lg/ml) and BM4627 (ciprofloxacin MIC, 32 ,ug/ml) were isolated from the same patient before and during pefloxcin therapy for septic tibial nonunion, respectively. The two strains had similar serotypes and indistinguishable phage types and SmaI-generated restriction fragment length polymorphisms. Portions of the gyrA (codons 60 to 120) and the gyrB (codons 420 to 480) genes of each clinical isolate were amplified by PCR and sequenced. Strain BM4627 had a serine-to-leucine substitution resulting from a cytosine-to-thymidine mutation at codon 84 of gyrA relative to the sequence of the gyrA gene of BM4626. Norfloxacin accumulation, measured in a whole-cell uptake assay, was significantly lower in BM4627 than BM4626. These data indicate that double mutants can be selected in vivo under fluoroquinolone therapy.
Fluoroquinolones are synthetic broad-spectrum antibiotics that were introduced in clinical practice in the early 1980s. They were initially active against methicillin-susceptible as well as methicillin-resistant strains of Staphylococcus aureus, a major community-acquired and nosocomially acquired pathogen. Unfortunately, fluoroquinolone resistance emerged and spread rapidly in this species, especially among methicillinresistant strains (15) .
Three mechanisms of resistance to fluoroquinolones have been described in -S. aureus. The first one consists of a mutational alteration of DNA gyrase, a topoisomerase which catalyzes ATP-dependent negative supercoiling of DNA and is thought to be the primary target for quinolone action (21) . The enzyme is a tetramer of two A and two B subunits, coded for by the gyrA and gyrB genes, respectively. In S. aureus (6, 16, 17) , like in Escherichia coli (4, 7, 23) , clustered point mutations in gyrA have been associated with fluoroquinolone resistance. Resistance in E. coli can also result from a mutation in gyrB (22) that has not been found in S. aureus. Active efflux of quinolones from the cell has been proposed as a second mechanism of resistance in S. aureus (9, 24) . The gene involved, norA, is part of the S. aureus chromosome and encodes a polypeptide that acts like a quinolone efflux pump. A third resistance locus, termed flqA, has been shown to be distinct from the structural genes for the DNA gyrase and from the norA gene, but the mechanism of resistance remains unknown (20) . The However, the precise contribution of gyrA mutations to resistance remains to be established.
We studied three pairs of fluoroquinolone-susceptible and -resistant matched clinical strains of methicillin-susceptible S. aureus isolated in three geographically distant hospitals. Each pair of strains was isolated from the same patient before and during pefloxacin therapy. S. aureus BM4626 and BM4627
were isolated from the pus of a patient with a septic tibial nonunion, BM4628 and BM4629 were isolated from bronchial aspirations of a polytraumatized patient, and BM4630 and BM4631 were isolated from the pus of a foot osteitis of a diabetic patient. The MICs of pefloxacin, norfloxacin, ciprofloxacin, and sparfloxacin for these strains were determined by dilution in agar with Mueller-Hinton medium and an inoculum of 104 CFU per spot ( Table 1) .
The strains were compared by serotyping (13) , phage typing (2), and pulsed-field gel electrophoresis analysis after SmaI digestion of total DNA. In the last technique, isolation, deproteinization, and restriction of DNA were performed as described previously (18) . Restriction fragments were separated in 1% agarose gels run at 200 V in 0.5 x Tris-borate-EDTA buffer by using a CHEF-DR II system (Bio-Rad Laboratories, Nazareth, Belgium). Optimal separation was achieved by using a 5-to 35-s-pulse-time linear gradient for 23 h. The two members of each pair had similar (BM4626 and BM4627; BM4630 and BM4631) or identical (BM4628 and BM4629) serotypes and phage types ( (10) . The gyrA portion from the resistant isolate BM4627 had a C-to-T transition at nucleotide position 251, resulting in a serine-to-leucine substitution at codon 84 (Ser-84 to Leu substitution). The partial gyrB sequences obtained were identical to (BM4630 and BM4631) or differed only by three silent mutations (BM4626, BM4627, BM4628, and BM4629) from that reported previously for S. aureus 601055 (3) .
An amino acid substitution similar to that found in GyrA of strain BM4627 has already been detected in methicillin-resistant strains of S. aureus (6, 16, 17) . Other substitutions in GyrA have also been associated with quinolone resistance in S. aureus: Ser-84 to Ala; Ser-85 to Pro, which can be associated with a Ser-84 to Leu substitution; and Glu-88 to Lys. These four substitutions are associated with high-level quinolone resistance (ciprofloxacin MICs, .16 ,ug/ml), as is the case in strain BM4627.
We also studied the kinetics of accumulation of norfloxacin by the six clinical isolates. The isogenic strains SA-1199 (quinolone susceptible; ciprofloxacin MIC, 0.25 Fg/ml) and SA-1199B (quinolone-resistant; ciprofloxacin MIC, 5 .96 Fg/ ml) were used as controls (9) . Norfloxacin accumulation in SA-1199B is significantly reduced compared with that in SA-1199 because of active efflux of the drug (9) . The modified fluorescence method described by Mortimer and Piddock (11) was used, with the final norfloxacin concentration being 20 ,ug/ml. The fluorescences of the cells were measured with a spectrofluorometer at excitation and emission wavelengths of 277 and 440 nm, respectively, and the data were expressed as nanograms of norfloxacin per milligram of protein (Fig. 1) . As in the control strains, norfloxacin accumulation in the resistant strain BM4627 was significantly reduced compared with that in the susceptible strain BM4626. Resistant strains BM4629 and BM4631 accumulated norfloxacin similarly to their respective susceptible counterparts BM4628 and BM4630 (data not shown). Resistance in SA-1199B is associated with enhanced activity of a chromosomally encoded protein, NorA, which actively exports fluoroquinolones from the cells, in particular, hydrophilic molecules (9) . Protein NorA and the closely related Bacillus subtilis protein Bmr are multidrug efflux transporters, and their activities are inhibited by the plant alkaloid reserpine (12) . At a concentration which does not affect bacterial growth (20 SA1199 is reduced only twofold (9) . Similar results were obtained for strains BM4627 and BM4626 (Table 1) . This suggests that a NorA-related efflux mechanism is involved in the reduced norfloxacin uptake of strain BM4627.
In conclusion, a minimum of two mechanisms account for high-level (64-fold increase in the ciprofloxacin MIC) fluoroquinolone resistance in strain BM4627: a mutation of the gyrA gene at position 251 resulting in a Ser-to-Leu substitution at position 84 of the GyrA protein and reduced accumulation of the drugs, probably involving NorA. So far, mutational alterations of GyrA have been found only in high-level fluoroquinolone-resistant strains of S. aureus. However, spontaneous high-level-resistant mutants of S. aureus cannot be selected in a single step (1, 8, 19) . Recently, a gyrA mutation similar to that present in BM4627 was found in second-step but not in first-step mutants of S. aureus obtained in vitro (8) . It was proposed that this gyrA mutation may occur only in strains of S. aureus that have already undergone another mutation. Our results indicate that the sequential acquisition of fluoroquinolone resistance in S. aureus also occurs in vivo.
The mechanism responsible for the low-level quinolone resistance of strains BM4629 and BM4631 remains unexplained. The reduction in the novobiocin MIC for strain BM4631 was slight (twofold) but reproducible compared with that for the parent strain. This observation suggests the presence of aflqA mutation, since it is known that mutations in this locus render the cells more susceptible to novobiocin (20) . Mutations in the nonsequenced regions of the genes for the DNA gyrase or drug impermeation not detected by the norfloxacin uptake experiment are also possible.
